Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Maintenance therapy for patients with advanced urothelial carcinoma

Simon Crabb, PhD, MBBS, Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK, discusses the evolving field of maintenance treatment for advanced urothelial carcinoma (UC). The ATLANTIS trial, investigating maintenance treatment in biomarker-defined subgroups of patients, was initially designed in accordance with the standard of care (SOC) for advanced UC, platinum-based chemotherapy followed by observation until second-line chemotherapy. However, since the study commenced, data has been released indicating a survival advantage for using nivolumab as maintenance treatment for this patient population. The results of the ATLANTIS trial will therefore be required to be interpreted in the context of nivolumab, such as if rucaparib where to be developed as maintenance treatment it is likely this will be in combination with immunotherapy.This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.